Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Inclusion Criteria

• •Patients must be 18 years of age
• •Patients must have histologically confirmed supratentorial Grade IV astrocytoma (glioblastoma multiforme)
• •Patients must not have prior radiation therapy, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy. Glucocorticoid therapy is allowed.
• •Patients must have recovered from the immediate post-operative period and be maintained on a stable corticosteroid regimen (on increase for 5 days) prior to the start of treatment.
• •Patients must have a Karnofsky performance of at least 60% or more.